Alembic has acquired the domestic non-oncology formulation business of Dabur Pharma for a consideration of Rs. 159 crores. The acquisition will be funded through a combination of internal accruals and debt. The company may also exercise the option of diluting a small portion of its equity. The consideration of Rs. 159 crores is for the acquisition plus the actual net working capital.
Read the Indiainfoline.com article.
Dealcurry: Capital Markets, Investment Banking, Private Equity 